drugset / Trial / NCT00253084

Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease

NCT00253084

Phase 2 Completed 12 enrolled Impax Laboratories, LLC
RandomizedCrossoverTriple-blindTreatment

Summary

The purpose of this study is to compare the clinical efficacy of IPX054 to immediate-release carbidopa-levodopa in subjects with Parkinson's disease.

Timeline

Start
2005-11
Primary completion
2007-12
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbidopa Unknown 25 mg
Subject Carbidopa Unknown 50 mg
Subject Levodopa Small molecule 100 mg
Subject Levodopa Small molecule 200 mg

Indications